SecBot SecBot
PRESS-RELEASE ·Filed Aug 17, 2026

HCM

HUTCHMED (China) Limited
BULLISH
Impact 8/10
Horizonweeks Processed3mo ago WireGlobeNewswire
Press release · FDA
Actionable Insight ▲ Bullish

This is a transformative catalyst for HUTCHMED, the SAFFRON data provide the global registration package for the ORPATHYS + TAGRISSO combination, which could expand the addressable market beyond China. Traders should watch for regulatory submission timelines (FDA, EMA) and potential partnership milestones from AstraZeneca. The stock may gap up significantly on this news given the high unmet need and biomarker-directed nature of the therapy.

DirectionBullish
Confidencehigh
Horizonweeks

Drugs in focus

HCM drug pipeline →

ORPATHYS

◆ Mixed Named in this press release
Impact
Phase
Approved in China (3 indications); global Phase 3 readout pending
Time to market
Already approved and marketed in China (lung cancer since 2021, gastric cancer July 2026). Ex-China (US/EU) approval is not filed yet — timing hinges on the SAFFRON global Phase 3 readout expected H2 2026.
Next catalyst
None dated

What to watchWatch for SAFFRON/SANOVO Phase 3 topline data in H2 2026, a positive readout supports global (ex-China) filings for savolitinib and would be the biggest near-term share-price lever; a miss or delay would hit a stock already near its 52-week low ($11.13 vs $18.30 high). HUTCHMED carries $1.37B cash, so the stock isn't a financing story, but this one drug's readout is the dominant H2 catalyst alongside sovleplenib NDA decisions.

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$12.64
T+0 close · Aug 18, 2026 · via day close
Latest settled
+21.68%
T+60 · $15.38
Vs SPY
+23.72%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Aug 18 $12.64entry
  2. T+1 · 3mo ago −0.40%α −0.61% · $12.59
  3. T+5 · 3mo ago −3.01%α −2.81% · $12.26
  4. T+20 · 2mo ago +6.49%α +8.23% · $13.46
  5. T+60 · 6d ago +21.68%α +23.72% · $15.38
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

HUTCHMED announced positive Phase III SAFFRON trial results showing savolitinib (ORPATHYS) plus osimertinib (TAGRISSO) significantly improved progression-free survival and overall survival vs chemotherapy in EGFR-mutant NSCLC patients with MET-driven resistance after TAGRISSO progression. This is a high-impact catalyst for global registration of the combination, addressing a large unmet need in a biomarker-defined population with no prior oral targeted option.

Key Facts

  • SAFFRON Phase III met primary endpoint of PFS and key secondary endpoint of OS with statistical significance and clinical meaningfulness
  • Trial enrolled 338 patients across 29 countries in 230 centers
  • Combination addresses MET overexpression/amplification, which occurs in ~34% of patients after third-generation EGFR TKI progression
  • ORPATHYS plus TAGRISSO already approved in China based on SACHI Phase III; SAFFRON supports global registrations
  • Safety profile consistent with known profiles of each medicine; no new safety findings
  • Data to be presented at forthcoming medical meeting and shared with global regulatory authorities

Financial Impact

Positive readout for a global Phase III trial in a large addressable NSCLC population with MET-driven resistance; potential to unlock multi-billion-dollar peak sales for the combination globally

revenuepipeline valueregulatory approval probability

Risk Factors

  • Regulatory timelines and approval decisions are uncertain; FDA/EMA may require additional data
  • Competition from other MET-targeted agents in development
  • Commercial uptake depends on biomarker testing adoption (MET IHC/FISH) in clinical practice
  • HUTCHMED CEO currently on leave of absence, which may create operational uncertainty

Market Snapshot

Exchange
OTC
Sector
Pharmaceutical Preparations
Analyst Consensus
85% bullish (26 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3345800

US Market Status

Market Closed · Opens in 6h 19m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 16, 2026